SCHEMBL25504106

SCHEMBL25504106

CCN1CCC(C)(NC(=O)c2cc(C)ncc2Cl)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 7/20 0.45
PKM P14618 1/20 0.36
P2RX7 Q99572 2/20 0.36
CCR3 P51677 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
HDAC3 O15379 2/20 0.35
HDAC4 P56524 2/20 0.35
HDAC1 Q13547 2/20 0.35
HDAC7 Q8WUI4 2/20 0.35
HDAC2 Q92769 2/20 0.35
HDAC10 Q969S8 2/20 0.35
HDAC11 Q96DB2 2/20 0.35
HDAC8 Q9BY41 2/20 0.35
HDAC6 Q9UBN7 2/20 0.35
HDAC9 Q9UKV0 2/20 0.35
HDAC5 Q9UQL6 2/20 0.35
S1PR1 P21453 1/20 0.35
CHRM1 P11229 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20069176 0.87 RET (0.44) RETP2RX7HDAC3HDAC4HDAC1
SCHEMBL25504101 0.86 RET (0.45) RETCCR3ALDH1A1HDAC1
SCHEMBL20147627 0.84 RET (0.43) RETP2RX7LMNAMAPT
SCHEMBL20158552 0.82 RET (0.42) RETP2RX7LMNAMAPT
SCHEMBL25504103 0.80 RET (0.43) RETCCR3ALDH1A1LMNAMAPT
SCHEMBL21652015 0.77 CHRM5 (0.53) CCR3ALDH1A1LMNAMAPTCHRM1
SCHEMBL20205890 0.76 MAPT (0.47) RETP2RX7CCR3ALDH1A1LMNA
SCHEMBL20205892 0.76 MT-CO2 (0.46) RETP2RX7CCR3CHRM1CHRM5
SCHEMBL21651966 0.75 P2RX7 (0.41) RETP2RX7CCR3ALDH1A1MAPT
SCHEMBL25504246 0.74 RET (0.43) RETP2RX7CCR3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 RET 1/4885PKM 1352/4885P2RX7 1456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.